Product Information
FELBAMATE 400 MG TABLET is a generic product labeled by ANI Pharmaceuticals, Inc., priced at $0.7978 per EA under NDC 62559073001. Its NADAC has been published 399 times since Feb 13, 2019.
FDA first approved this application on Nov 4, 2015. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
400 mg/1
Manufacturer
ANI Pharmaceuticals, Inc.NDC
62559073001
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
FELBAMATEApproval Type
Generic (ANDA)
FDA Application
ANDA202284FDA Approved
11/4/2015
TE Code
AB
On Market Since
9/4/2018
Pharmacological Classes
Price Statistics
The NADAC for FELBAMATE 400 MG TABLET has been published 399 times since Feb 13, 2019, and over the history we have for it it has declined 69.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7978 per EA |
|---|---|
| All-time high | $3.2846 (Oct 16, 2019) |
| All-time low | $0.6785 (Jul 22, 2026) |
| 52-week high | $1.0316 |
| 52-week low | $0.6785 |
| Median price | $1.1756 |
| Average price | $1.6113 |
| Largest weekly change | -59.2% (Oct 21, 2020) |
| Weeks tracked | 399 |
| Tracking since | Feb 13, 2019 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
ANI Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Felbamate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anti-epileptic Agent class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FELBAMATE 400 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for FELBAMATE 400 MG TABLET, manufactured by ANI Pharmaceuticals, Inc., is $0.7978 per EA (NDC 62559073001), effective Sep 30, 2026.
How has the price of FELBAMATE 400 MG TABLET changed over time?
Over the history we have for it, the NADAC for FELBAMATE 400 MG TABLET has declined 69.2%. It has been tracked across 399 weekly CMS publications since Feb 13, 2019.
What are the highest and lowest recorded NADAC prices for FELBAMATE 400 MG TABLET?
Since Feb 13, 2019, the NADAC for FELBAMATE 400 MG TABLET has ranged from a low of $0.6785 (Jul 22, 2026) to a high of $3.2846 (Oct 16, 2019), with a median of $1.1756 per EA.
Are there cheaper alternatives to FELBAMATE 400 MG TABLET?
4 manufacturers publish a NADAC-priced product with the same active ingredient and strength as FELBAMATE 400 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures FELBAMATE 400 MG TABLET?
FELBAMATE 400 MG TABLET (NDC 62559073001) is labeled by ANI Pharmaceuticals, Inc., and CMS classifies it as a generic product.